Louise Chen

Shares of Gilead Sciences Inc (NASDAQ:GILD) rallied in early trading on Wednesday after the company reported upbeat fourth-quarter results. Here are the key analyst insights: Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating, while raising the price target from $135 to $155....

Although Eli Lilly And Co (NYSE:LLY) reported its fourth-quarter revenues and earnings ahead of consensus estimates, backed by higher sales of Zepbound and Mounjaro, according to Scotiabank. The Eli Lilly Analyst: Analyst Louise Chen maintained a Sector Outperform rating, while raising the price...

President Joe Biden’s Inflation Reduction Act, which allows Medicare to negotiate the price of some prescription drugs, remains the talk of the town as investors sell off shares in pharmaceutical companies such as Pfizer Inc. (NYSE: PFE) because drugs associated with the companies...

Shares of Eli Lilly And Co (NYSE: LLY) Tuesday spiked, after the company reported strong second-quarter results. The results came amid an exciting earnings season. Here are some key analyst takeaways from the earnings release. Cantor Fitzgerald On Eli Lilly Analyst Louise Chen maintained an...

Pfizer Inc. (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) announced positive results Wednesday from a late-stage study of the COVID-19 vaccine BNT162b2 in adolescents. The Pfizer Analyst: Cantor Fitzgerald analyst Louise Chen maintained an Overweight rating on Pfizer with a $...

Pfizer Inc. (NYSE: PFE) andBioNTech SE – ADR (NASDAQ: BNTX) have managed to stay ahead in the vaccine race by a hair's breadth. Within days after Moderna Inc (NASDAQ: MRNA) released its first interim analysis, the U.S.-German combo announced results from the final analysis of their...

The first Interim data from an ongoing, late-stage coronavirus trial by Pfizer Inc. (NYSE: PFE) is expected sometime after the U.S. presidential elections, according to an analyst at Cantor Fitzgerald. The Pfizer Analyst: Louise Chen has an Overweight rating and $53 price target for Pfizer...

Amarin Corporation plc (NASDAQ: AMRN) shares were advancing strongly Tuesday following the release Tuesday of second-quarter results. What Happened: Amarin reported second-quarter revenue of $135.3 million, up 34% year-over-year, but below the $149.48-million consensus estimate. "...

Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...

The data shows more positives about Pfizer’s (NYSE: PFE) coronavirus vaccine candidate and remains in-line with its German partner BioNTech’s (NASDAQ: BNTX) study, according to Cantor Fitzgerald Securities. The Pfizer Analyst: Louise Chen maintained an Overweight rating on...

Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa.  The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price...

Pfizer Inc. (NYSE: PFE) shares declinded Monday after the company said that a Phase 3 breast cancer treatment study — known as "PALLAS" — is unlikely to hit the primary goal, citing efficacy and futility analysis done by an Independent Data Monitoring...

Merck & Co., Inc. (NYSE: MRK) announced a trio of initiatives Tuesday to combat the coronavirus pandemic.  The Kenilworth, New Jersey-based, large-cap biopharma announced two partnerships: one to develop an antiviral treatment and another to develop a vaccine. In a third deal,...

Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance. The Merck Analysts Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107 price target. SVB Leerink analyst Daina Graybosch...

Amarin Corporation plc (NASDAQ: AMRN) shares were tumbling Tuesday in reaction to a negative verdict issued by a U.S. District Court regarding generic versions of its fish oil pill Vascepa. Amarin shares, which rose to 52-week high of $26.12 in mid-December in reaction to a Vascepa...